Oral anti diabetic polychemotherapy in type 2 diabetes mellitus

Diabetes and Metabolism

Volumn 28, Issue 5, 2002, Pages 350-353

  Gin, Henri ^a   Rigalleau, V ^a  

^a Groupe Hospitalier Sud CHU de Bordeaux   (France)

Author keywords

Oral antidiabetic drugs; Type 2 diabetes melitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; METFORMIN; NATEGLINIDE; REPAGLINIDE; SULFONYLUREA; THIAZOLIDINE DERIVATIVE;

ADIPOCYTE; BODY MASS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSTPRANDIAL STATE; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0036860243     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. De Fronzo RA. The triuvirate: β-Cell, muscle, liver. A collusion responsible for NIDDM. Diabetes, 1988, 37, 667-670.
2. Calles-Escandon J, Robbins DC. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes, 1987, 36, 1167-1172.
3. UKPDS. Perspectives in Diabete: U.K. Prospective Diabetes Study 16. Overview of 6 years'therapy of type II diabetes: A progressive disease. Diabetes, 1995, 44, 1249-1258.
4. Gin H, Rigalleau V. Post-prandial hyperglycemia. Post-prandial hyperglycemia and diabetes. Diabet Metab, 2000, 26, 265-272,
5. Turner RC, Cull CA, Frighi V, Holman RR, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. JAMA, 1999, 281, 2005-2012.
6. Federici M, Hribal M, Perego L et al. High glucose causes apoptosis in cultured human pancreatic islets of langerhans. A potential role for regulation of specific Bcl family genes toward an apoptotic cell eath programm. Diabetes. 2001, 50, 1290-1301.
7. Donath MY, Gross DJ, Cerasi E, Kaiser N. Hyperglycemia-induced β-cell apoptosis in pancreatic islets of psammomys obesus during development of diabetes. Diabetes, 1999, 48, 738-744.
8. Kaiser N, Donath MY, Gross DJ, Cerasi E. Diabète non insulinodépendant et apoptose des cellules bêta. Flammarion Médecine Sciences 1999; Journées de Diabétologie.
9. Freinkel N. Of prégnancy and progeny. Diabetes, 1980, 29. 1023-1035.
10. De Fronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaires tissue glucose Uptake. Metabolism, 1989, 38, 387-395.
11. Inzucchi SE, David MD, Maggs G et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Eng J Med, 1998, 338, 867-872.
12. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris prospective study. Diabetes Care, 1991, 14. 461-469.
13. Avignon A, Radauceanu A, Monnier L. Non fasting plasma glucose is better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997, 20, 1822-1825.
14. Gutniak M, Orskov C, Holts JJ, Ahren B, Effendric S. Antidiabetogenic effects of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Eng J Med. 1992, 326. 1316-1322.
15. Clissold SP, Edwards C. Acarbose: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs, 1998, 35, 214-243.
16. UK Prospective Diabetes Study Group. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care, 1998, 21, 87-92.
17. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 12.
18. Olsson J, Lindberg G, Gottater M et al. Increased mortality in type 2 diabetic patients using sulfonylurea and metformin in combination: A population-based observational study. Diabetologia, 2000, 43, 558-560.
19. Moses R, Slobodnuk R, Boyages S. Effect of repaglinides addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care, 1999, 22, 119-124.
20. Wolffenbuttel BHR, Gomist R, Squatrito S, Jones NP, Patwardhans RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabetic Medicine, 2000, 17, 40-47.
21. Horton ES, Whitehouse F, Ghazzi M et al. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care, 1998, 21, 1462-1469.
22. Raskin P, Jovanovic L, Berger S et al. Repaglinidle/troglitazone combination therapy. Diabetes Care, 2000, 23, 979-983.
23. Perriello G, Misericordia P, Volpi E et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Diabetes, 1994, 43, 920-928.
24. Saltiel A, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 1996, 45, 1661-1669.
25. Fonseca V, Rosenstock J, Patwardhan R, Salzman A, Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial, JAMA, 2000, 283, 1695-1702.
26. Yale JF, Valiquett TR, Ghazzi MN et al. The effect of a thiazolidinedione drug, troglitazone on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin, Ann Inte Med, 2001, 134, 737-745.
27. Jones N, Jones T, Menci L, Xu J et al. Rosiglitazone in combination with glibenclamide plus metformin is effective and well tolerated in type 2 diabetes patients Diabetologia, 2001, 44, A235.
28. Chiasson JL, Naditch L. The synergistic effect of miglitol plus metformin combination therapyin the treatement of type 2 diabetes. Diabetes Care, 2001, 24, 989-994.
29. Lam KS, Tiu SC, Tsang MW, Tam S. Acarbose in NIDDM patients with poor control on conventional oral agents. Diabetes Care, 1998, 21, 1154-1161.